T Ertveldt

Thomas Ertveldt is a junior postdoc at the VUB’s Molecular Imaging and Therapy (MITH) research group. He recently concluded his doctoral studies revolving the immunogenic properties of targeted radionuclide therapy (TRT) mediated by single domain antibodies (sdAb’s) and immune imaging upon immune intervention. With his research, he aspires to improve knowledge and tools to increase patients response as well as reduce adverse effects to novel therapies such as TRT and immunotherapy.

Thomas Ertveldt is a junior postdoc at the VUB’s Molecular Imaging and Therapy (MITH) research group. He recently concluded his doctoral studies revolving the immunogenic properties of targeted radionuclide therapy (TRT) mediated by single domain antibodies (sdAb’s) and immune imaging upon immune intervention. With his research, he aspires to improve knowledge and tools to increase patients response as well as reduce adverse effects to novel therapies such as TRT and immunotherapy.